These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 1618262)
1. The potent 5-HT3 receptor antagonist (R)-zacopride labels an additional high affinity site in the central nervous system. Kidd E; Bouchelet de Vendegies I; Levy JC; Hamon M; Gozlan H Eur J Pharmacol; 1992 Jan; 211(1):133-6. PubMed ID: 1618262 [TBL] [Abstract][Full Text] [Related]
2. Characterisation of the non-5-HT3 high-affinity 'R' binding site for (R)-zacopride in brain and other tissues. Kidd FJ; Levy JC; Nielsen M; Hamon M; Gozlan H Eur J Pharmacol; 1993 Sep; 247(1):45-56. PubMed ID: 8258360 [TBL] [Abstract][Full Text] [Related]
3. Common pharmacological and physico-chemical properties of 5-HT3 binding sites in the rat cerebral cortex and NG 108-15 clonal cells. Bolaños FJ; Schechter LE; Miquel MC; Emerit MB; Rumigny JF; Hamon M; Gozlan H Biochem Pharmacol; 1990 Oct; 40(7):1541-50. PubMed ID: 2222509 [TBL] [Abstract][Full Text] [Related]
4. [(125I)iodo-zacopride: new ligand for the study by autoradiography of central 5-HT3 receptors]. Koscielniak T; Ponchant M; Laporte AM; Guminski Y; Verge D; Hamon M; Gozlan H C R Acad Sci III; 1990; 311(6):231-7. PubMed ID: 2121314 [TBL] [Abstract][Full Text] [Related]
5. Differential binding characteristics of agonists at 5-HT3 receptor recognition sites in NG108-15 neuroblastoma-glioma cells labelled by [3H]-(S)-zacopride and [3H]granisetron. Barnes JM; Barnes NM Biochem Pharmacol; 1993 May; 45(10):2155-8. PubMed ID: 8390263 [TBL] [Abstract][Full Text] [Related]
6. Distribution of S(-)-zacopride-insensitive [125I]R(+)-zacopride binding sites in the rat brain and peripheral tissues. Ge J; Barnes JM; Towers P; Barnes NM Eur J Pharmacol; 1997 Aug; 332(3):307-12. PubMed ID: 9300265 [TBL] [Abstract][Full Text] [Related]
7. The (S)-isomer of [3H]zacopride labels 5-HT3 receptors with high affinity in rat brain. Waeber C; Pinkus LM; Palacios JM Eur J Pharmacol; 1990 Jun; 181(3):283-7. PubMed ID: 2384135 [TBL] [Abstract][Full Text] [Related]
9. Quantitative autoradiographic mapping of 5-HT3 receptors in the rat CNS using [125I]iodo-zacopride and [3H]zacopride as radioligands. Laporte AM; Koscielniak T; Ponchant M; Vergé D; Hamon M; Gozlan H Synapse; 1992 Apr; 10(4):271-81. PubMed ID: 1585260 [TBL] [Abstract][Full Text] [Related]
10. The differential activities of R (+)- and S(-)-zacopride as 5-HT3 receptor antagonists. Barnes JM; Barnes NM; Costall B; Domeney AM; Johnson DN; Kelly ME; Munson HR; Naylor RJ; Young R Pharmacol Biochem Behav; 1990 Dec; 37(4):717-27. PubMed ID: 2128757 [TBL] [Abstract][Full Text] [Related]
11. [3H]zacopride: ligand for the identification of 5-HT3 recognition sites. Barnes NM; Costall B; Naylor RJ J Pharm Pharmacol; 1988 Aug; 40(8):548-51. PubMed ID: 2907008 [TBL] [Abstract][Full Text] [Related]
12. Use of stereoisomers of zacopride to analyze actions of 5-hydroxytryptamine on enteric neurons. Wade PR; Mawe GM; Branchek TA; Gershon MD Am J Physiol; 1991 Jan; 260(1 Pt 1):G80-90. PubMed ID: 1987811 [TBL] [Abstract][Full Text] [Related]
13. Characterisation and autoradiographic localisation of 5-HT3 receptor recognition sites identified with [3H]-(S)-zacopride in the forebrain of the rat. Barnes JM; Barnes NM; Champaneria S; Costall B; Naylor RJ Neuropharmacology; 1990 Nov; 29(11):1037-45. PubMed ID: 2087255 [TBL] [Abstract][Full Text] [Related]
14. Physicochemical properties of serotonin 5-HT3 binding sites solubilized from membranes of NG 108-15 neuroblastoma-glioma cells. Miquel MC; Emerit MB; Bolaños FJ; Schechter LE; Gozlan H; Hamon M J Neurochem; 1990 Nov; 55(5):1526-36. PubMed ID: 2213008 [TBL] [Abstract][Full Text] [Related]
15. Differential modulation of extracellular levels of 5-hydroxytryptamine in the rat frontal cortex by (R)- and (S)-zacopride. Barnes NM; Cheng CH; Costall B; Ge J; Naylor RJ Br J Pharmacol; 1992 Sep; 107(1):233-9. PubMed ID: 1384906 [TBL] [Abstract][Full Text] [Related]
16. Antagonism of [3H]zacopride binding to 5-HT3 recognition sites by its (R) and (S) enantiomers. Pinkus LM; Sarbin NS; Gordon JC; Munson HR Eur J Pharmacol; 1990 Apr; 179(1-2):231-5. PubMed ID: 2364986 [TBL] [Abstract][Full Text] [Related]
17. Comparison of the 5-HT3 receptor antagonist properties of ICS 205-930, GR38032F and zacopride. Cohen ML; Bloomquist W; Gidda JS; Lacefield W J Pharmacol Exp Ther; 1989 Jan; 248(1):197-201. PubMed ID: 2521513 [TBL] [Abstract][Full Text] [Related]
18. Zacopride, a potent 5-HT3 antagonist. Smith WW; Sancilio LF; Owera-Atepo JB; Naylor RJ; Lambert L J Pharm Pharmacol; 1988 Apr; 40(4):301-2. PubMed ID: 2900319 [TBL] [Abstract][Full Text] [Related]
19. 5-HT3 receptor agonism may be responsible for the emetic effects of zacopride in the ferret. Middlefell VC; Price TL Br J Pharmacol; 1991 May; 103(1):1011-2. PubMed ID: 1831684 [TBL] [Abstract][Full Text] [Related]
20. Involvement of tryptophan residue(s) in the specific binding of agonists/antagonists to 5-HT3 receptors in NG108-15 clonal cells. Miquel MC; Emerit MB; Gozlan H; Hamon M Biochem Pharmacol; 1991 Sep; 42(7):1453-61. PubMed ID: 1930269 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]